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General remarks 
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General remarks 
Introduction 
Osteoarthritis (OA) is the most common form of arthropathy, and the major cause of disability 
in the elderly. Histological studies of osteoarthritic joints show that the prominent change is the 
loss of hyaline cartilage from part or whole of the articular surface, accompanied by new bone 
formation (osteophyte).  
 
Contrary to rheumatoid arthritis (RA), synovitis has been considered as a secondary 
phenomenon not associated with systemic inflammation, but it is responsible for symptom of 
OA. Although inflammation and immune response is unlikely to play a primary role in initiating 
synovitis, growing evidence have shown that inflammation accelerates articular degeneration. 
Proinflammatory cytokines are produced in the inflamed synovium and diffuse into the cartilage. 
They activate chondrocytes, in turn, which could produce other catabolic factors such as 
interleukin-1 (IL-1) and tumor necrosis factor (TNF)a (Pellitier et al., 2001). 
 
Among various chemical mediators, IL-1 has been revealed to play a central role in degradation 
of articular cartilage (Van de Loo et al., 1995); it is produced by mononuclear cells in arthritic 
synovium (Farahat et al., 1993) and chondrocytes (Moos et al., 1999). IL-1b  stimulates the 
proliferation of synoviocytes (Kumkumian et al., 1989) and enhances the production of various 
chemical mediators such as IL-6 (Guerne et al., 1989), prostaglandin E2 (PGE2) (Moos et al., 
1999) and nitric oxide (NO) (Stefanovic-Racic et al., 1994) from synoviocytes. IL-1b  also 
stimulates the production of PGE2 (Campbell et al., 1990), NO (Stadler et al., 1991), matrix 
metalloproteases (MMPs) Tetlow et al., 2001), and chemokines (Yuan et al., 2001) from 
chondrocytes. 
 
MMPs are important molecules that induce cartilage depletion in OA. MMP-1 and MMP-13 
cleave predominantly type II collagen (Billinghurst et al., 1997), and MMP-3, also known as 
stromelysin-1, degrades proteoglycans (Okada et al., 1992). Activated chondrocytes in OA 
produce these MMPs and degrade extracellular matrix surrounding them. PGE2, an 
inflammatory mediator, is involved in the homeostasis of chondrocytes (Fulkerson et al., 1983) 
and enhances pain (Ferreira et al., 1978). Chondrocyte-derived NO directly breaks down 
cartilage matrix and induces chondrocyte apoptosis (Hashimoto et al., 1998; Pelletier et al., 
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2000). Regulated upon activation, normal T cell expressed and secreted (RANTES) is a C-C 
chemokine, and is also called CCL5. RANTES has been shown to be involved in articular 
degradation, enhancing MMP-3 production by OA chondrocytes and suppressing 
proteoglycan production by OA chondrocytes (Yuan et al., 2001).  
 
Hyaluronan (HA) is a major component of extracellular matrix, and is found in most organs and 
tissues. HA comprises a repeat of N-acetylglucosamine and D-glucuronic acid. Intra-articular 
injections of HA have been widely accepted as one of the OA therapy. Although HA has 
generally regarded as a lubricant, several lines of evidences suggest its pharmacological effects 
on cells. HA inhibits production of MMP-1 (Shimizu et al., 2003) and PGE2 (Yasui et al., 1992) 
by OA synoviocytes. HA also suppresses production of PGE2 by rabbit articular chondrocytes 
(Akatsuka et al., 1993), and enhances proteoglycan synthesis in bovine articular cartilage 
(Fukuda at al., 1996). However, the response of chondrocytes to HA, specifically its effects on 
production of MMPs and chemokines from human OA chondrocytes, has not been clearly 
demonstrated.  
 
Glucosamine is aminosugar that is formed from fructose in vivo by glutamin-fructose-6-
phosphate amidotransferase and composes various glycosaminoglycans, the major component of 
extracellular matrix such as articular cartilage (Hugenberg et al., 1993). Nutraceutical 
glucosamine has been used as a supplement for the treatment of osteoarthritis for decades, 
possibly because the extracellular matrix was believed to wear out in OA cartilage. Many 
clinical results were reported (McAlindon et al., 2000) and some in vitro studies have been 
published on the effects of glucosamine on chondrocytes or articular cartilage (Piperno et al., 
2000; Bassleer et al., 1998; Gouze et al., 2001; Shikhman et al., 2001). However, the effects of 
glucosamine on synoviocytes have not been fully investigated.  
 
OA has been generally considered to be a degenerative joint disease caused by biomechanical 
alterations. However, recent studies have revealed that endogenous articular cartilage 
components have been found to provide a rich source of antigenic determinants in these diseases 
(Goldberg et al., 1987; Poole et al., 1992). It is proposed that the  exposure of cartilage 
components to the immune system may consequently induce autoimmune arthritis, initiating the 
production of catabolic factors including MMPs. These factors then degrade the cartilage matrix, 
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and re-expose cartilage antigens to the immune system, which leads to an autoimmune reaction 
to the cartilage in OA. As a result, such autoimmune reactions could cause further destruction of 
the cartilage (Figure A). 
 
Figure A. Schematic diagram of the involvement of mechanical and immune-
mediated pathways in the cartilage degradation of osteoarthritis. IL -1: 
interleukin-1; TNFa: tumor necrosis factor a; MMPs: matrix metalloproteases; 
NO: nitric oxide; PGs: prostaglandins. (Yuan et al., 2003) 
 
Sakata et al (2003) revealed that OA chondrocytes expressed costimulatory molecules CD80 
and CD86 as well as MHC class II. They also demonstrated that OA chondrocytes stimulated 
autologous T cell proliferation and the response was inhibited by monoclonal antibodies against 
class II MHC, suggesting an interaction between chondrocytes and T cells via surface molecules. 
Involvement of this reaction in OA pathogenesis is, however, remain uninvestigated.  
 
Recently, Shibakawa et al (2003) reported that 90% of articluar samples from advanced OA 
patients had pannus- like tissue. Contrary to RA pannus, which had been extensively studied 
(Bresnihan et al., 1999), little attention has been paid to this non-cartilaginous tissue covering 
OA cartilage. Shibakawa et al (2003) showed that pannus- like tissue was preferentially located 
in the marginal region of the joint and could be classified into the vascular type and the fibrous 
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type. From the detailed histological observation, they speculated that the tissue was reparative in 
the earlier stage of OA, but changed to be catabolic after the long-term exposure to factors such 
as cytokines or growth factors involved in OA (Shibakawa et al., 2003). However, the 
phenotype and function of the cells in pannus- like tissue has not been well investigated, so far.  
 
The aims of this study were: (1) to clarify roles of chondrocytes and synoviocytes on OA 
progression in terms of MMP and chemokine production. (2) to investigate mode of action of 
anti-OA drugs, specifically HA and glucosamine. (3) to seek novel mechanisms of OA 
pathongenesis by demonstrateing chondrocyte-T cell interaction and (4) identifying 
characteristics of isolated cells from OA pannus-like tissue. 
 
Summary of this study 
Since the main pathological legion of OA is articular cartilage, chondrocytes are considered to 
be one of the key players in pathogenesis of OA. In Chapter I, the role of chondrocytes was 
evaluated by detecting MMP-1 and RANTES production. In addition, effect of hyaluronan, one 
of the most frequently used anti-OA drugs, was evaluated in order to clarify its mechanism of 
action. As results, HA suppressed IL-1b-induced production of MMP-1 and RANTES from OA 
chondrocytes in a molecular-weight-dependent manner. It was revealed that sensitivity of the 
cells to HA was enhanced due to higher expression of CD44 in OA chondrocytes. This result 
provides a rationale of HA therapy on OA treatment. 
 
In Chapter II, chondrocyte-T cell interaction was investigated from the view point of the  
production of MMPs and RANTES. In addition, it was attempted to find an evidence that 
chondrocytes encounter T cells in vivo. The production of MMP-1, MMP-3, MMP-13, and 
RANTES was enhanced by direct co-culture compared to indirect co-culture using Transwell. 
Our results demonstrated that chondrocyte-T cell interaction is a possible new pathway of 
cartilage degeneration. 
 
In Chapter III, we determined the effects of glucosamine hydrochloride on chondrocytes and 
synoviocytes in terms of PGE2, NO, and MMPs production. Glucosamine hydrochloride had 
pharmacological effects on chondrocytes and synoviocytes by inhibition of IL-1 stimulated 
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production of PGE2, NO, MMP-1, MMP-3 and MMP-13. Glucosamine modulated IL-1 
stimulated production of PGE2, NO, MMP-1, MMP-3 and MMP-13 from chondrocytes and 
synoviocytes, and its mode of action differed between cells and conditions. This result explains 
pharmacological mode of action of glucosamine. 
 
In Chapter IV, the characteristics of cells isolated from pannus- like tissue were identified, 
aiming at evaluating the role of this tissue in OA.  It was demonstrated that OA pannus cells 
shared the properties of mesenchymal cells and chondrocytes, however, their origin seemed 
different from synobviosytes or chondrocytes. The spontaneous expression of MMPs suggests 
that they are involved in the articular degradation in OA. 
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1. Suppressive effects of hyaluronan on MMP-1 and RANTES 
production from chondrocytes 
1.1 Introduction 
Hyaluronan (HA) is a major component of extracellular matrix, and is found in most organs and 
tissues. HA comprises a repeat of N-acetylglucosamine and D-glucuronic  acid. Binding of HA to 
its receptor causes cellular locomotion and migration, and HA plays an important role during 
development and differentiation (Laurent et al., 1992). HA also acts as an immunomodulator, by 
activating antigen-presenting cells such as dendritic cells and macrophages (Termeer et al., 
2003). Most of these responses are mediated by HA-CD44 interaction.  
Activity of HA seems to depend on the size of the HA molecule. Fragmented HA, but not high-
molecularweight HA, induces release of chemokines such as MIP-1a, MIP-1b, MCP-1 and 
RANTES from alveolar macrophages (McKee et al., 1996). In a human chondrosacoma cell line, 
low-molecular-weight fragmented HA (3,500 Da) upregulates expression of unokinase-type 
plasminogen activator, inducing production of MAP kinase proteins (Kobayashi et al., 2002). In 
contrast, HA of various molecular weights (range 250-2,000 kD) suppresses TNF-induced 
production of MMP-1 by synoviocytes (Shimizu et al., 2003).  
In osteoarthritis (OA) (Hamburger et al., 2003; Miltner et al., 2002), articular cartilage is 
degraded by multiple factors, and chondrocytes play an important role in development of OA, 
by expressing metalloproteinases (MMPs) (Shlopov et al., 1997), prostaglandin E2 (PGE2) and 
nitric oxide (NO) (Nakamura et al., 2004). MMPs cleave collagen fiber, and some MMPs also 
digest proteoglycan in articular cartilage. Expression of these mediators is enhanced by 
interleukin-1 (IL-1), and they promote degradation of articular cartilage (Van de Loo et al., 
1995). Regulated upon activation, normal T cell expressed and secreted (RANTES) is a C-C 
chemokine, and is also upregulated by IL-1 in chondrocytes. RANTES has also been shown to 
be involved in articular degradation, enhancing MMP-3 production by OA chondrocytes and 
suppressing proteoglycan production by OA chondrocytes (Yuan et al., 2001). 
Hyaluronan inhibits production of MMP-1 (Shimizu et al., 2003) and PGE2 (Yasui et al., 1992) 
by OA synoviocytes. HA also suppresses production of PGE2 by rabbit articular chondrocytes 
(Akatsuka et al., 1993), and enhances proteoglycan synthesis in bovine articular cartilage  
(Fukuda et al., 1996). The response of chondrocytes to HA, specifically its effects on production 
of MMPs and chemokines, has aroused our interest. In our preliminary experiments, production 
of MMP-1 and RANTES by IL-1b-stimulated chondrocytes was clearly inhibited by HA. In the 
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present study, we used human OA chondrocytes to examine the effects of HA of various 
molecular weights on the production of MMP-1 and RANTES by IL-1b-stimulated 
chondrocytes, and to examine the involvement of CD44, a major HA-binding receptor, in these 
effects. 
 
1.2 Patients and methods 
1.2.1 Patients 
Human articular cartilage samples were obtained from 12 patients with knee OA who underwent 
total knee replacement (age range, 47-79 years; mean, 66.4 years). All patients met the 
American College of Rheumatology criteria (Altman et al., 1986). Cartilage from ten patients 
with femoral neck fracture who underwent prosthetic surgery (age  range, 70-94 years; mean, 
81.1 years) was used as the control. Articular cartilage from the control samples showed no 
arthritic findings macroscopically or microscopically. All samples were obtained with informed 
consent from the patients, and the study protocol was approved by the institutional ethical 
committee. 
 
1.2.2 Chondrocyte culture 
Cartilage was minced, and was digested by shaking overnight at 37°C in Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco BRL, NY, USA) containing 0.1% bacterial collagenase (Sigma, 
MO, USA). The cells released by enzymatic digestion were filtered through a sterile nylon 
strainer (Becton Dickinson Labware, UK), washed, and centrifuged. The pellet was seeded on 
dishes (Iwaki, Funabashi, Japan) at a density of 5-10×105 cells/ dish, in DMEM containing 10% 
fetal calf serum (FCS; Gibco BRL, Rockville, MD, USA), 100 units/ml penicillin (Gibco BRL) 
and 100 mg/ml streptomycin (Gibco BRL). The dishes were incubated at 37°C in a humidified 
atmosphere of 5% CO2. Medium was replaced twice a week, and cells were used within the 
second passage. 
 
1.2.3 Effects of HA on production of MMP-1 and RANTES 
Chondrocytes were prepared from seven OA samples and five control samples. HA of various 
molecular weights (1.2, 50, 800 and 1,900 kD) was provided by Denkikagaku Kogyo (Tokyo, 
Japan). To evaluate the suppressive effects of HA on production of MMP-1 and RANTES, 
chondrocytes were seeded onto 24-well plates (Iwaki, Japan) at 5×104 cells/well, and were 
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incubated for 24 h to allow cells to adhere to the plates. Cells were pre-treated with 1 mg/ml HA 
in DMEM containing 10% FCS for 24 h. The media were replaced with serum- free DMEM 
containing 1 mg/ml HA and 5 ng/ml recombinant human IL-1b  (R&D Systems, Minneapolis, 
MN, USA) for 24 h. The culture supernatants were collected and stored at -30°C until they were 
used for enzyme-linked immunosorbent assay (ELISA). Cell viability, which was evaluated by 
lactate dehydrogenase (LDH) assay using a LDH cytotoxicity detection kit (TaKaRa, Japan), 
was not affected under these experimental conditions (data not shown). Concentrations of 
MMP-1 and RANTES in culture media were quantified by ELISA according to the respective 
manufacturer’s instructions (BIOTRACK MMP-1 ELISA system, Amersham Pharmacia 
Biotech, UK; Quantikine human RANTES immunoassay, R&D Systems). 
 
1.2.4 Quantitative real-time polymerase chain reaction (PCR) assay for MMP-
1 and RANTES expression 
MMP-1 and RANTES expression of chondrocytes treated with HA was examined at a message 
level.  Chondrocytes from six OA patients were prepared as described above, and were treated 
with 1 mg/ml 800- and 1,900-kD HA together with 5 ng/ml IL-1b. Total RNA was extracted 
from the chondrocytes using the single-step guanidinium-thiocyanate-phenol chloroform 
method (ISOGEN; Nippon Gene, Japan). Firststrand complementary DNA (cDNA) was made 
from total RNA with a cDNA construction system, using Superscript II reverse transcriptase 
(Gibco BRL, USA) and following the manufacturer’s protocol. TaqMan primers and TaqMan 
probes for human MMP-1 and RANTES were designed with the assistance of Primer Express 
software (Applied Biosystems, Netherlands). The sequences were as fo llows: MMP-1 5’ primer, 
-GGGAGATCATCGGGACAACTC; -MMP-1 3’ primer, 5’-GGGCCTGGTTGAAAAGCAT-
3’; MMP-1 probe, -AGCAAGATTTCCTCCAGGTCCATCAAAAGG- 3’; RANTES 5’ primer, 
-CTGCATCTGCCTCCCCATAT-; RANTES 3’ primer, AGTGGGCGGGCAATGTAG; 
RANTES probe, - CTCGGACACCACACCCTGCTGCT. PCR reactions were performed using 
the ABI Prism 7700 Sequence Detection System (Applied Biosystems) with 100 ng of cDNA 
templates (5 ml), 900 nM each primer, 200 nM probes, and 25 ml of TaqMan Universal Master 
Mix (Roche, IN, USA) in a final volume of 50 ml. PCR cycling consisted of denaturation at 
95°C for 10 min, and 45 cycles of denaturation at 95°C for 15 s and extension at 60°C for 1 min. 
Relative expression levels of MMP-1 and RANTES mRNA were quantified and normalized to 
human b-actin. Expression of MMP-1 and RANTES mRNA by HA-treated chondrocytes was 
recorded as relative levels, compared to expression by chondrocytes stimulated with IL-1b. 
Chapter I: Effects of hyaluronan on MMP-1 and RANTES production from chondrocytes  
9 
 
1.2.5 Anti-CD44 antibody blocking assay 
Chondrocytes from six OA patients were prepared as described above. Prior to treatment with 5 
ng/ml IL-1b and 1 mg/ml HA (1,900 kD) for 24 h at 37°C, cells were incubated with 1 mg/ml 
anti-CD44 antibody (clone 5F12, Neomarkers, USA) for 2 h at 37°C in DMEM. Culture 
supernatants were collected, and MMP-1 and RANTES concentrations were determined by 
ELISA. 
 
1.2.6 Flow cytometric analysis 
To detect expression of CD44, chondrocytes were analyzed by flow cytometric analysis. 
Chondrocytes from six OA patients and five control subjects were seeded onto six-well plates at 
a concentration of 1.5×105 cells/well in DMEM containing 10% FCS, followed by incubation 
for 24 h at 37°C. The media were replaced by serum-free DMEM with 5 ng/ml IL-1b for 24 h at 
37°C. Cells were collected by trypsinization, washed twice with PBS, blocked with Blockace 
(Snow Brand, Japan), and incubated for 30 min at 4°C with anti-CD44 antibody conjugated with 
fluorescein isothiocyanate (FITC) (clone J173; Immunotech, France) or FITC-conjugated 
isotype-control mouse IgG (Immunotech). Finally, cells were suspended in 500 ml of PBS, and 
were immediately analyzed by FACScan (Becton Dickinson, MA, USA). Mean fluorescent 
intensity was calculated using Cell-Quest analysis software (Becton Dickinson). 
 
1.2.7 Statistical analysis 
All values were expressed as mean ± SE. Statistical significance of differences between groups 
(production of MMP-1 and RANTES, and mean intensity of CD44 expression) was analyzed by 
Student’s t test. Relative expression of MMP-1 and RANTES mRNA was analyzed using the 
Mann-Whitney U test. 
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1.3 Results 
1.3.1 Effects of HA on IL -1-stimulated MMP-1 and RANTES production 
Prior to this study, we performed preliminary experiments to assess effects of HA on production 
of MMP-1, MMP-3, MMP-9, RANTES and MCP-1 (data not shown) by IL-1-stimulated OA 
chondrocytes. Because MMP-1 and RANTES were clearly suppressed by 1 mg/ml HA 
treatment, we selected MMP-1 and RANTES as indicators of effects of HA treatment. Without 
IL-1b stimulation, the levels of MMP-1 in OA chondrocytes and controls were 23.4±8.6 and  
6.1±4.4 ng/ml respectively, and RANTES levels in OA chondrocytes were 41.4±25.0 pg/ml and 
below the limit of detection in controls. After stimulation with IL-1b, the levels increased 
dramatically: MMP-1 in OA, 125.1±42.3 ng/ml; MMP-1 in controls, 96.5±15.5 ng/ml; 
RANTES in OA, 506.2±121.5 pg/ml; RANTES in controls, 425.0±90.6 pg/ml. In OA 
chondrocytes, enhanced production of MMP-1 and RANTES production were partly suppressed 
in a molecular-weight-dependent manner; suppression of MMP-1 by 800- and 1,900-kD HA 
was significant, and suppression of RANTES by 1,900-kD HA was significant (Fig. 1). 
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Fig. 1 MMP-1 and RANTES production from OA chondrocytes and control cells. 
Chondrocytes were pre-treated with 1 mg/ml of 1.2-, 50-, 800-, and 1,900-kD HA in 
DMEM containing 10% FCS for 24 h and then incubated with 5 ng/ml IL-1b 
together with respective HA in serum-free medium for another 24 h. Supernatant 
was collected, and MMP-1 and RANTES were measured by ELISA. MMP-1 in  OA 
chondrocytes (a), RANTES in OA chondrocytes (b), MMP-1 in control cells (c) 
and RANTES in control cells (d). Values are the mean ± SE (n=7 in OA 
chondrocytes and n=5 in control) and analyzed by Student’s t test. ND not 
detected. *p<0.05  
 
1.3.2 Effects of HA on MMP-1 and RANTES mRNA Expression 
The suppressive effect of HA on MMP-1 and RANTES mRNA expression in OA chondrocytes 
was confirmed by real- time PCR. Both MMP-1 and RANTES expression were enhanced by IL-
1b stimulation. HA suppressed the expression of MMP-1 and RANTES mRNA in a molecular-
weight-dependent manner; suppression by 1,900-kD HA was significant (Fig. 2). 
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Fig. 2 Real time PCR for MMP-1 (a) and RANTES (b) mRNA expression. 
Chondrocytes were treated as in Fig. 1 and the effects of 800- and 1,900-kD HA 
were evaluated under the stimulation of 5 ng/ml IL-1b. The intensity of respective 
messages were normalized with b-actin expression. Values are mean ± SE (n=6) 
and analyzed using Mann-Whitney U test. *p<0.05 
 
1.3.3 Involvement of CD44 in suppressive effects of HA 
IL-1-stimulated OA chondrocytes were treated simultaneously with 1,900-kD HA and anti-
CD44 antibody. The suppressive effect of HA on MMP-1 production was canceled by pre-
treatment with anti-CD44 antibody, which blocks binding between CD44 and HA (Fig. 3). In 
contrast, the suppressive effect of HA on RANTES production was not affected by anti-CD44 
antibody (data not shown). 
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Fig. 3 Inhibition of HA effects by anti-CD44 antibody. OA chondrocytes were pre-
incubated with 1 µg/ml of anti-CD44 antibody in serum-free DMEM for 2 h, 
followed by stimulation with 5 ng/ml of IL-1b in the presence of 1,900-kD HA for 
24 h. Then the supernatant was evaluated for MMP-1 by ELISA. Values are mean 
± SE (n=6) and analyzed using Student’s t test. *p<0.05 
 
1.3.4 Flow cytometry analysis of expression of CD44 on chondrocytes 
To examine differences in cellular response to HA between OA and controls, expression levels 
of CD44 on chondrocytes were evaluated. Figure 4a shows the representative data of flow 
cytometry for OA and control chondrocytes. The peak fluorescent intensity was clearly higher 
for OA chondrocytes than control cells without stimulation by IL-1b. Because the suppressive 
effects of HA were detected in chondrocytes stimulated by IL-1b, CD44 expression by IL-1b-
stimulated chondrocytes was also evaluated. Mean fluorescent intensity (MFI) for CD44 was 
significantly higher for OA chondrocytes than for controls, with or without stimulation by IL-1b. 
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Fig. 4 Expression of CD44 on chondrocytes. Chondrocytes were cultured with or 
without 5 ng/ml IL-1b in serum-free DMEM for 24 h and subjected to flow 
cytometric analysis. (a) A representative result of OA chondrocytes (solid line) 
and control (broken line). Gray area indicates isotype-control mouse IgG -FITC. 
(b) Mean fluorescent intensity (MFI) of CD44 expressions OA chondrocytes (open 
column) and control (hatched column). Values are mean ± SE and analyzed using 
Student’s t test. **p<0.01, *p<0.05 
 
1.4 Discussion 
Osteoarthritis is a joint disease characterized by degradation and wear of articular cartilage, 
synovitis, and  remodeling of underlying bone. It has been demonstrated that inflammation is 
involved in the pathogenesis of OA (Smith et al., 1997; Geuerassimov et al., 1999; Nakamura et 
al., 1999). In OA, proinflammatory cytokines such as IL-1 and tumor necrosis factor-a (TNFa) 
stimulate production of MMPs (Yoshihara et al., 2000) and suppress production of extracellular 
matrix components such as glycosaminoglycan (GAG) and type II collagen. 
Several lines of evidence show that molecular weight of HA is a critical factor in the cellular 
responses induced by HA (MacKee et al., 1996; Kobayashi et al., 2002). High-molecular-
weight HA has been used to treat OA, and has an analgesic effect when it is injected into joint 
cavities (Miltner et al., 2002). At present, molecular weight of HA in clinically-available 
preparations is greater than 615 kD (Lo et al., 2003), but the present results indicate that 1,900-
kD HA suppresses MMP-1 and RANTES production more effectively than HA of lower 
molecular weight. Such effects are absent in very small HA fragments (e.g., <20 kD), which can 
even have harmful effects on physiological responses (MacKee et al., 1996; Kobayashi et al., 
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2002). The finding that molecular weight of HA is a critical factor in its cellular effects indicates 
that it is important to discriminate HA according to molecular weight. We propose the term 
“macro-hyaluronan” (MHA) to describe HA with a molecular weight greater than 1000 kD. 
In the present study, 800-kD HA suppressed MMP-1 production by OA chondrocytes, and 
MHA (1,900-kD) suppressed both MMP-1 and RANTES production by OA chondrocytes; HA 
with lower molecular weight had no such effects. The present results indicate that suppressive 
effects of HA on MMP-1 production are mediated by HA-CD44 interaction, which is consistent 
with previous findings (MacKee et al., 1996; Julovi et al., 2004). However, the question remains 
why fragmented HA has no such suppressive effects, despite the fact that CD44 is a common 
receptor for both MHA and fragmented HA. A possible explanation is clustering of CD44 
molecules (Liu et al., 1997), which is a prerequisite for dimerization of CD44 that enhances 
affinity of HA for CD44. MHA may cluster CD44 molecules more effectively than HA with 
lower molecular weights. Another possibility is a degradation system such as internalization of 
HA via CD44 (Culty et al., 1992)or digestion by hyaluronidases (Flanney et al., 1998). It may 
be more difficult to degrade or digest MHA than lower-molecular-weight HA. 
The mode of cellular response to HA appears to differ among cell types. In the present study, 
only OA chondrocytes responded to HA by suppression of IL-1-stimulated MMP-1 production. 
This difference is partly explained by the finding that CD44 expression is higher in OA 
chondrocytes than in controls, even with stimulation by IL-1b. Suppression of RANTES 
expression may be mediated by a different mechanism, using other HA-binding proteins such as 
RHAMM (Turley et al., 2002). 
In conclusion, MHA suppressed production of MMP-1 and RANTES by OA chondrocytes. The 
effects of HA were partly mediated by CD44. These findings  are consistent with the 
chondroprotective effects of intra-articular injection of HA in OA patients. 
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1.5 Summary 
The purpose of the study was to examine the effects of hyaluronan (HA) on human 
chondrocytes in terms of production of MMP-1 and RANTES. Chondrocytes were obtained 
from patients with osteoarthritis (OA) or femoral neck fracture (control). Chondrocytes in 
monolayer culture were treated with various molecular weights (1.2, 50, 800 and 1,900 kD) of 
HA and then stimulated with IL-1b. Production and expression of MMP-1 and RANTES were 
quantified by ELISA and real-time polymerase chain reaction (PCR). The response was blocked 
by anti-CD44 antibody. Production of MMP-1 was significantly suppressed by both 800- and 
1,900-kD HA, while production of RANTES was suppressed by 1,900-kD HA. Expression of 
MMP-1 and RANTES mRNA was inhibited by 1,900-kD HA. Suppressive effects of HA on 
production of MMP-1 were canceled by treatment of anti-CD44 antibody. Higher CD44 
expression was found in OA chondrocytes than in those of control. High-molecular-weight HA 
suppressed MMP-1 and RANTES production, mediated partly by CD44-HA interaction. 
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2. Enhanced production of MMP-1, MMP-3, MMP-13, and RANTES 
by interaction of chondrocytes with autologous T cells 
2.1 Introduction 
Osteoarthritis (OA) is the most common form of arthritis characterized by degeneration and 
gradual loss of articular cartilage. Contrary to rheumatoid arthritis (RA), synovitis has been 
considered as a secondary phenomenon not associated with systemic inflammation, but it is 
responsible for symptom of OA. Although inflammation and immune response is unlikely to 
play a primary role in initiating synovitis, growing evidence have shown that inflammation 
accelerates articular degeneration. Proinflammatory cytokines are produced in the inflamed 
synovium and diffuse into the cartilage. They activate chondrocytes, in turn, which could 
produce other catabolic factors such as interleukin-1 (IL-1) and tumor necrosis factor (TNF)a  
(Pellitier et al., 2001).  
Furthermore, cellular immunity might be implicated in the pathogenesis of OA. Activated T 
cells, B cells and monocyte/macrophages infiltrated into synovial tissue  and they were proven to 
be immunocompetent (Revell et al., 1988; Sakkas et al., 1998). In addition, these T cells were 
clonally expanded with some  specific T cell receptors (Nakamura et al., 1999) suggesting that 
they were autoreactive to specific antigens.  
Degradation products of cartilage matrix such as a fragment of type II collagen, proteoglycan, 
G1 domain of aggrecan and link protein are candidates of autoantigens in OA (Hansen et al., 
1996; Guerassimov et al., 1999). Cartilage intermediate layer protein (CILP) and YKL-39, 
secreted proteins from chondrocytes were reported as autoantigens in OA and they could induce 
mild arthritis in mice when they were immunized (Tsuruha et al., 2001; Yao et al., 2004; Sakata 
et al., 2003; Tsuruha et al., 2002). 
As chondrocytes were segregated from vessels and lymphatic system by ample of cartilage 
matrix, they have been believed to be privileged from immunity, though the articular component 
provides fertile antigenic determinants. Chondrocytes have been reported to process and present 
antigens expressing MHC class II molecules (Lance et al., 1993; Alsalameh et al., 1991). Our 
previous study showed that peripheral mononuclear cells and T cells reacted to autologous 
chondrocytes via HLA molecules, CD4 or CD8 and the concept of immune mediated 
mechanism in OA was suggested (Sakata et al., 2003). However, little evidence of in vivo 
interaction between chondrocytes and lymphocytes has been reported and the response of 
chondrocyte-T cells has not been elucidated at all. 
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Matrix metalloproteases (MMPs) are critical molecules that induce cartilage depletion in OA. 
MMP-1 and MMP-13 predominantly cleave type II collagen (Billinghurst et al., 1997), and  
MMP-3, also known as stromelysin-1, catalyzes proteoglycan and activates other proenzymes 
(Okada et al., 1992). These MMPs are produced by chondrocytes as well as synoviocytes 
especially when stimulated by IL-1 (Nakamura et al., 2004). Chemokines were found as 
chemotactic factors secreted by lymphocytes, monocytes or granulocytes. Regulated upon 
activation, normal T cell expressed and secreted (RANTES) and its receptor, CCR-5 were 
expressed in chondrocytes and the production of RANTES was enhanced by IL-1b  and TNFa. 
RANTES acted as a catabolic factor, as it not only induced MMP-3 but also suppressed the 
synthesis of proteoglycan from chondrocytes (Yuan et al., 2001). 
In this study, the response of chondrocyte-T cell interaction was investigated from the view 
point of the production of MMPs and RANTES and the possible  evidence of contact of 
chondrocytes with T cells in vivo was examined. 
 
2.2 Materials and methods 
2.2.1 Samples 
Articular cartilage was obtained from nine OA patients who underwent total knee arthroplasty. 
The patients were composed of two males and seven females (the mean age of 63.4 years 
ranging from 62 to 79) and were diagnosed as primary OA fulfilling the ACR criteria (Altman et 
al., 1986). Non-arthritic cartilage samples were obtained from five patients with traumatic injury 
who underwent prosthetic  surgery of the hip (the mean age of 86.5 years ranging from 80 to 94). 
Their articular cartilage appeared normal macroscopically and microscopically. Peripheral 
blood samples were collected from the patients approximately 1 month after the surgery, when 
chondrocytes grew enough for the experiments. Synovial fluid (SF) was obtained from the knee 
joints of seven patients with OA (the mean age of 66.8 years raging from 57 to 75) for detection 
of chondrocyte-like cells and T cells. All samples were obtained with informed consent from the 
patients and the study protocol was approved by the institutional ethical committee. 
 
2.2.2 Isolation and preparation of chondrocytes 
Cartilage specimens were minced and digested by rotating overnight at 37°C in Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco BRL, NY, USA) containing 0.1% collagenase 
(Sigma, MO, USA). The cells were filtered with a 100-mm cell strainer following plating on 
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type I collagen-coated dish in DMEM containing 10% fetal bovine serum (FCS; Gibco BRL), 
and chondrocytes were used for the experiments at the first passage. 
 
2.2.3 Preparation of T cells from peripheral blood 
Peripheral blood mononuclear cells (PBMCs) were prepared by the standard density gradient 
centrifugation method using Ficol-paque Research Grade (Amersham Pharmacia Biotech AB, 
Sweden). T cells were isolated from the PBMCs by a T-cell enrichment column kit (R&D 
systems, Minneapolis, USA) (Sakata et al., 2003). The purity of CD3+ cells in the recovered 
cells ranges between 85 and  95%, according to the manufacture’s instruction. The viability of T 
cells was confirmed by stimulation with 5 mg/ml phytohemagglutinin (PHA; Sigma).  
 
2.2.4 Co-culture of chondrocytes with autologous T cells  
Chondrocytes were seeded onto 24-well plates at 5×104 cells per well in 10% FCS/DMEM for 
24 h to allow cells to adhere on the plates and cultured alone or co-cultured with 1×105 
autologous T cells for 72 h,  which permit “direct contact” of both cells. In other wells, 
chondrocytes were “separated” from T cells by Transwell (Corning, NY, USA). MMP-1, MMP-
3, MMP-13, and RANTES levels in the culture supernatant were measured by commercially 
available ELISA kits according to the respective manufacturer` s instructions (MMP-1 and 
MMP-13; Amersham Pharmacia Biotech, UK, MMP-3; Daiichi Pure Chemicals, Japan, 
RANTES; R&D systems). The results were expressed as the production ratio (PR), which was 
calculated by following formula: 
 
            [D] or [S] 
Production ratio (PR)   =   ――――――― 
            [C] + [T] 
 
([C]: MMPs or RANTES levels in supernatant of chondrocyte culture, [T]: those of T cell 
culture, [D]: those of direct contact co-culture, [S]: those of separated co-culture with 
Transwell) 
The PR was calculated by the average of triplicated experiments of co-culture from individual 
samples. 
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2.2.5 Detection of T cells in SF 
To detect T cells in SF, samples were treated with 1 mg/ml of bovine testis type-I hyaluronidase 
(Sigma, MO, USA) for 20 min at 37°C and centrifuged at 3,000 rpm for 15 min at 4°C. 
Mononuclear cells in SF (SFMCs) were separated by a standard density centrifugation method 
using Ficoll-Paque (Amersham Pharmacia Bioteck, UK), suspended in 1% normal mouse serum 
for blocking for 30 min, incubated with FITC labeled anti-human CD3 antibody (Becton 
Dikinson, CA, USA) for 30 min on ice, and counted with a fluorescent microscope (Fig. 4a). 
 
2.2.6 Detection of chondrocyte-like cells in SF and the articular surface 
Chondrocytes- like cells in SF was confirmed by Alcian blue staining that reacted to 
glucosaminoglycan, a component of cartilage matrix. SF samples were dispensed onto 24-well 
plates at 0.5 ml/well and incubated at 37°C for 24 h to allow cells to adhere. The plates were 
washed by phosphate buffered saline (PBS) twice, fixed with 10% neutral buffered formalin at 
room temperature (RT) for 2 h, and stained with 1% Alcian blue (pH1.0, Wako Pure Chemical, 
Japan) at RT for 1 h. Cells with matrix positive for Alcian blue were counted as chondrocyte-
like cells (Fig. 4b). 
To examine chondrocytes in the lacerated surface, specimens of OA cartilage were stained with 
Alcian blue. Briefly, a part of cartilage blocks from OA patients were fixed by 4% 
paraformaldehyde for 5 days at 4°C, demineralized with 20% EDTA (pH 7.4) at 4°C for 7 days, 
and embedded in paraffin. The samples were cut into 5 mm sections. The sections were stained 
with 1% Alcian blue at RT for 1 h and were examined by a light microscopy. 
 
2.2.7 In vitro contact of chondrocytes and T cells 
Chondrocytes were seeded on eight-well chamber slides (Nunc, Naperville, IL, USA) at a 
density of 5×104 per well and were cultured for 5 days in conditioned medium until 
chondrocytes reached semi-confluent. In some chambers, freshly isolated autologous PBMC 
were added at a density of 5×104 per well following further culture for 24 h. As controls, 
chondrocytes and PBMC were incubated alone in the same condition. Each chamber was 
washed twice with PBS to remove nonadherent cells and fixed with acetone on ice for 30 min. 
Slides were washed with PBS containing 0.1% Tween 20 twice, blocked by BlockAce 
(Dainippon Pharmaceutical Co., Japan) for 30 min on ice and incubated by 0.05 mg/ml of FITC 
labeled anti-human CD3 antibody (Becton Dikinson, CA, USA) for 30 min on ice. Then the 
slides were embedded in fluorescent mounting medium (DAKO, CA, USA) and examined by 
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fluorescent  microscopy and phase contrast microscopy. The number of positive cells was 
counted in the randomly selected three fields under 40-magnification. 
 
2.2.8 Reverse transcriptase-polymerase chain reaction 
Reverse transcriptase-polymerase chain reaction (RTPCR) was applied to SF cells, 
chondrocytes and T cells. Briefly, totalRNAwas isolated from cells using ISOGEN (Nippon 
Gene, Japan) according to the manufacture’s instructions. Complementary DNA (cDNA) was 
made from total RNA by a cDNA construction system using Superscript II reverse transcriptase 
(Gibco BRL, NY, USA) following the manufacture’s protocol. Primers sets used for RT-PCR 
were listed in Table 1. For detecting aggrecan and type II collagen in SF cells, nested PCR was 
used. The first PCR was performed for 35 cycles at 94°C for 1 min, 58°C for 1 min, and 72°C 
for 1 min for aggrecan,  94°C for 1 min, 50°C for 1 min, and 72°C for 1 min for type II collagen 
a1 chain (COL2A1), and 94°C for 1 min, 62°C for 1 min, and 72°C for 1 min for GAPDH in a 
PCR Thermal Cycler (TAKARA BIO INC., Japan). In the second PCR, the first PCR products 
were amplified for 35 cycles at 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min for 
aggrecan and GAPDH, and 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min for COL2A1. 
To detect the expression of MMP-1, MMP-3, MMP-13, and  RATNES, T cells were prepared in 
10% FCS/RPMI 1640 (Iwaki) and stimulated with 5 mg/ml PHA for 72 h at 37°C. Each cDNA 
was amplified for 35 cycles at 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min for MMPs 
and GAPDH, and for 35 cycles at 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min for 
RANTES. PCR products were electrophoresed on 1.5% agarose gels, stained with ethidium 
bromide (10 mg/ml), and visualized under ultraviolet illumination. 
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Table 1 Sequence of primers and corresponding size of RT-
PCR for aggrecan, COL2A1, MMP-1, MMP-3, MMP-13, RANTES, 
and GAPDH 
   Nested PCR 
Aggrecan 
   First PCR (398 bp) 
Forward 5’-ATCATTGCCACGCCTGAGCA-3’ 
Reverse 5’-TTGGAGATGGGGTAGCGCAC-3’ 
   Second PCR (125 bp) 
Forward 5’-GTTTCCTGGTGTGAGGACGTA-3’ 
Reverse 5’-CCTGGAAGGTGAACTTCTCTG-3’ 
COL 2A1 
   First PCR (500 bp) 
Forward 5’-CAGGACCAAAGGGACAGAAA-3’ 
Reverse 5’-CCTTTCACCAGCTTTTCCAG-3’ 
   Second PCR (204 bp) 
Forward 5’-TCGTGGTGACAAAGGTGAAA-3’ 
Reverse 5’-CCCATTGGTCCTTGCATTAC-3’ 
GAPDH 
   First PCR (598 bp) 
Forward 5’-CCACCCATGGCAAATTCCATGGCA-3’ 
Reverse 5’-TCTAGACGGCAGGTCAGGTCCACC-3’ 
   Second PCR (544 bp) 
Forward 5’-CTGAGAACGGGAAGCTTGTCA-3’ 
Reverse 5’-TGACACGTTGGCAGTGGGGA -3’ 
   Regular PCR 
MMP-1 (428 bp) 
Forward 5’-CTGAAGGTGATGAAGCAGCC-3’ 
Reverse 5’-AGTCCAAGAGAATGGCCGAG-3’ 
MMP-3 (440 bp) 
Forward 5’-CCTCTGATGGCCCAGAATTGA-3’ 
Reverse 5’-GAAATTGGCCACT CCCTGGGT-3’ 
MMP-13 (491 bp) 
Forward 5’-GACTTCACGATGGCATTGCTG-3’ 
Reverse 5’-GCATCAACCTGCTGAGGATGC-3’ 
RANTES (370 bp) 
Forward 5’-TCATTGCTACTGCCCTCTGC-3’ 
Reverse 5’-CGTCGTGGTCAGAATCTGGG-3’ 
 
2.2.9 Statistical analysis 
All the values were expressed as the mean ± SD. PRs between direct contact and separated co-
culture were analyzed by Wilcoxon’s test and those between OA and non-arthritis samples were 
analyzed by Mann-Whitney U-test. 
 
2.2.10 Influence of hyaluronan on MMP production induced by chondrocyte-T 
cell contact 
To examine the influence of HA on the enhanced PR of MMP-3 which is induced by 
chondrocyte-T cell contact, cells were cultivated in 24-well plates as follows: chondrocyte alone 
Chapter II: Interaction of chondrocytes with autologous T cells  
23 
(C), chondrocytes alone but in the presence of 1 mg/mL of hyaluronan (HA, molecular weight 
1,900 kDa) in the culture media (C+HA), co-culture of chondrocytes and autologous T cells 
(C+T), or co-culture of chondrocyts and T cells with 1 mg/mL of HA in the culture media 
(C+T+HA). MMP-3 concentration in the each culture media was determined by enzyme linked 
immunosorbent assay (ELISA). Changes in the MMP-3 production were expressed as PR which 
was calculated by the formula described in 2.2.4. 
 
2.3 Results 
2.3.1 Co-culture of chondrocytes with autologous T cells 
The mean PRs of MMP-1, MMP-3, MMP-13, and RANTES in separated co-culture of seven 
OA samples were 0.96±0.10, 0.90±0.12, 1.02±0.26, and 0.98±0.14, respectively, whereas those 
in direct contact co-culture were 1.20±0.13, 1.11±0.16, 1.22±0.33, and 1.59±0.82, respectively 
(Fig. 1). The PRs increased by 23% (MMP-3) to 62% (RANTES) with statistical significance 
(P<0.05, Fig. 1a-d). As T cells did not express MMPs even if stimulated with PHA confirmed 
by RT-PCR (Fig. 2) and ELISA (data not shown), MMPs were produced exclusively by 
chondrocytes and the production was enhanced by the direct contact with autologous T cells in 
OA. On the contrary, the enhanced production of RANTES was possibly due to both activated 
chondrocytes and T cells. 
 
Fig. 1 Production ratio (PR) of MMP-1 (a), MMP-3 (b), MMP-13 (c), and RANTES (d) 
in OA. Enhanced productions were shown in direct contact coculture of 
chondrocytes and autologous T cells. S separated co-culture, DC direct contact 
co-culture. *P<0.05 
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Fig. 2 Representative result of RT-PCR. Synovial T cells did not express MMP-1, 
MMP-3, and MMP-13 even stimulated with PHA, whereas T cells expressed 
RANTES and its expression was enhanced by PHA 
 
2.3.2 Responses of direct contact in OA and non-arthritic samples 
To compare the responses of direct contact in OA and non-arthritic  conditions, the levels of 
MMPs and RANTES in co-culture supernatant were investigated in nine OA and five non-
arthritic samples. The PRs of MMP-1, MMP-3, and MMP-13 showed no significant differences 
between them, whereas the PR of RANTES in OA was significantly higher than non-arthritic 
samples (P<0.05) (Fig. 3). 
 
Fig. 3 Production ratio (PR) of MMP-1 (a), MMP-3 (b), MMP-13 (c), and RANTES (d) 
in direct contact co-culture of chondrocytes and autologous T cells in OA and 
non-arthritis  samples. PR in RANTES was significantly higher in OA samples. N  
non-arthritic  samples, OA OA samples. *P<0.05 
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2.3.3 Detection of T cells and chondrocyte-like cells in SF 
In SF, mononuclear cells were found at a density of 4.4±1.1×104 cells/ml and the most of them 
were positive for CD3 (Fig. 4a). Cells that were surrounded by Alcian blue positive matrix were 
found in SF at a density of 0.63±0.08 cells/ml (Fig. 4b). Histological findings of lacerated 
surface of OA cartilage showed that chondrocytes were exposed or just detached from cartilage  
into joint cavity (Fig. 4c). The latter finding suggested that Alcian blue positive cells in SF were 
derived from cartilage. Expression of aggrecan was detected in three out of seven SF cell 
samples by nested RT-PCR (Fig. 5a) and one of the samples expressed COL2A1 (Fig. 5b). 
Though the total cell number that showed chondrocyte phenotype might be small, these data 
suggested the presence of chondrocyte- like cells in SF. 
 
Fig. 4 (a) Fluorescent image of synovial cells showed the presence of CD3 
positive cells. (b) Cells surrounded by Alcian blue positive matrix was detected 
in the synovial fluid at a density of 0.63 ± 0.08 cells/ml. (c) Alcian blue staining 
showed that chondrocytes were exposed or just detached from cartilage in the 
lacerated articular surface. Bar 100 mm 
 
Fig. 5 RT-PCR of showed that three of seven synovial fluid cells  from OA 
expressed aggrecan (a). One of the samples expressed COL2A1 (b). C  
chondrocyte, SF synovial fluid cells 
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2.3.4 In vitro contact of chondrocytes and autologous T cells 
Chondrocytes-T cell contact was reproduced by in vitro co-culture system. CD3 positive cells 
were retained in the chamber slide predominantly in OA when they were co-cultured with 
chondrocytes (Fig. 6a-d). The average number of CD3 positive cells was significantly greater in 
OA (Fig. 6e) 
Fig. 6 CD3 positive cells were retained in co-culture with chondrocytes. Phase 
contrast image of co-culture (a, b). Fluorescent image of CD3 positive cells (c, d). 
Co-culture of OA sample (a, c) and nonarthritic  sample (b, d). Cell count of CD3 
in randomly selected five fields showed more T cells were retained in OA after 
wash (e). Bar 100 mm. *P<0.05 
 
2.3.5 Effects of hyaluronan on MMP production induced by chondrocyte-T 
cell contact 
A significant increase of PR was observed in direct contact co-culture of chondrocytes and 
autologous T cells (C+T group) compared with chondrocytes alone (C group) (Fig.7). The 
increase of PR was completely suppressed in the group in which chondrocytes and T cells were 
co-cultured in the presence of HA (C+T+HA). 
 
 
 
Chapter II: Interaction of chondrocytes with autologous T cells  
27 
 
Fig.7 Production ratio (PR) of MMP-3 in direct contact co-culture of chondrocytes 
and autologous T cells in OA samples, and effect of hyaluronan on the PR. PR in 
RANTES was significantly  higher in OA samples. C chondrocytes alone, C+HA 
chondrocytes alone in the presense of 1 mg/ml of HA, C+T direct contact co-
culture of chondrocytes and autologous T cells, C+T+HA direct contact co-
culture of chondrocytes and T cells in the presense of 1 mg/ml of HA.  *P<0.05 
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2.4 Discussion 
Chondrocytes share an antigen presenting property mediated by HLA antigens and express 
vascular cell adhesion molecule 1 (VCAM-1) and/or intercellular adhesion molecule 1 (ICAM-
1) permitting chondrocytes to adhere to other cells such as T cells (Jobanputra et al., 1992; 
Kienzle et al., 1998; Horner et al., 1995). Thus, T cells are able to adhere to chondrocytes, 
especially when T cells are activated. In the present data, T cells were demonstrated to adhere to 
chondrocytes in vitro especially in osteoarthritic condition. 
It has been revealed that degraded product could be a candidate of autoantigen in OA and some 
of them induced arthritis in animal models [5-10]. Although, antigens are usually presented by 
antigen presenting cells (APCs) in the lymph nodes or synovial tissue, chondrocytes might be 
one of the APCs in cartilage. Our previous study clearly showed that the chondrocyte-T cell 
interaction was mediated via CD and HLA molecules and resulted in enhanced thymidine 
uptake by T cells, and this response was completely blocked by antibodies against these 
molecules (Sakata et al., 2003). Though T cells might be activated by chondrocyte derived 
matrix components such as fibronectin and type II collagen, chondrocyte-T cell contact was the 
major pathway of T cell activation in this study. 
The question arises whether such interaction is involved in the pathogenesis of OA and how the 
chondrocytes respond. To solve this question, co-culture of chondrocytes with autologous T 
cells were performed. As a result, PRs of MMP-1, MMP-3, MMP-13, and RANTES in the 
direct co-culture were significantly higher than those in the separated co-culture by Transwell in 
OA. MMP production by chondrocytes was enhanced by coculture with T cells, whereas 
enhanced RANTES production was possibly due to chondrocytes or T cells. When the PRs in 
direct co-culture were compared between OA and non-arthritic samples, the PRs of RANTES 
was significantly higher in OA. Thus, it was speculated that enhanced-production of MMPs 
were mediated by cellular adhesion itself and that of RANTES was partly mediated by 
activation of chondrocytes and T cells under the condition of OA. The production of MMPs was 
enhanced also in non-arthritic samples, however chondrocytes never encounter T cells in normal 
condition. 
A cell count of SF is not more than 1×105/ml in the normal condition, whereas that in 
noninflammatory diseases ranges from 2×105 to 2×106/ml (Ashman,1994). The cell count of OA 
SF in our series was an average of 4.4×104/ml and relatively low compared to the previous 
reports, probably because the cells were separated as mononuclear cells from SF. CD3 positive 
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cells in SF were supposed to be originated from activated T cells infiltrating into synovial tissue 
in OA (Sakkas et al., 1998; Nakamura et al., 1999). 
In the damaged surface of OA cartilage, we found that chondrocytes were peeled off from 
articular cartilage and were exposed to the joint cavity. Depletion of chondrocytes depends on 
apoptosis in a large part (Hashimoto et al., 1998), however, mechanical tear-off might be one of 
the causes of chondrocyte depletion in OA. This hypothesis was supported by the findings that 
chondrocyte- like cells were present in SF expressing aggrecan and COL2A1 in some cases. 
These results suggest that there is a possibility of chondrocyte-T cell contact in vivo, though 
chondrocytes are privileged from immune system in the normal condition. Limitations of this 
suggestion are lack of direct evidence of chondrocyte-T cell contact in vivo, quite small number 
of chondrocyte- like cell in SF and possible interference with the contact by matrix surrounding 
chondrocyte- like cells. 
Matrix metalloproteases and RANTES are catabolic factors that devastate articular cartilage and 
aggravate OA. Although a practical chance of chondrocyte-T cell contact is not so frequent, the 
responses caused by the contact might be one of the mechanisms of developing OA. 
 
Chapter II: Interaction of chondrocytes with autologous T cells  
30 
2.5 Summary 
It has been reported that T cells and chondrocytes interact through cell surface molecules such 
as MHC, CD4 or CD8 in osteoarthritis (OA) and T cells are activated. The objective of this 
study is to investigate the responses of chondrocyte-T cell interaction in terms of 
metalloprotease (MMP) and chemokine production. Articular cartilage and autologous blood 
were obtained from patients with OA and fracture who under went prosthetic surgery. Synovial 
fluid (SF) was collected from OA patients. Isolated chondrocytes were co-cultured with 
autologous T cells. SF cells were analyzed by immunostaining or Alcian blue staining. The 
production of MMP-1, MMP-3, MMP-13, and regulated on activation, normal T expressed and 
secreted (RANTES) was enhanced by direct co-culture compared to indirect coculture using 
Transwell. Production ratio of RANTES in OA was significantly higher than non-arthritic 
samples. CD3 positive mononuclear cells and chondrocyte- like cells were found in SF. 
Chondrocyte-T cell contact was more adhesive in OA samples. These results showed the 
production of MMPs and RANTES was enhanced by the interaction and that chondrocyte-T cell 
contact was possible in vivo. 
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3. Effects of glucosamine hydrochloride on the production of 
prostaglandin E2, nitric oxide and metalloproteases by 
chondrocytes and synoviocytes in osteoarthritis. 
3.1 Introduction 
Glucosamine is aminosugar that is formed from fructose in vivo by glutamin-fructose-6-
phosphate amidotransferase and composes various glycosaminoglycans, the major component of 
extracellular matrix such as articular cartilage (Hugenberg et al., 1993). Hyaluronic acid and 
keratan sulfate are gigantic polymers of the disaccharides found in cartilage, both of which 
consist of N-acetyl glucosamine and galactose or glucuronic acid. Metabolism of 
glycosaminoglycan together with that of collagen fibers is important in maintaining matrix of 
articular cartilage and the disruption of balance between synthesis and breakdown causes 
osteoarthritis (OA). 
Biological and chemical factors as well as mechanical factors are involved in the pathogenesis 
of OA. Among various chemical mediators, interleukinl-1 (IL-1) has been revealed to play a 
central role in degradation of articular cartilage (Van de Loo et al., 1995); it is produced by 
mononuclear cells in arthritic synovium (Farahat et al., 1993) and chondrocytes (Moos et al., 
1999). IL-1b  stimulates the proliferation of synoviocytes (Kumkumian et al., 1989) and 
enhances the production of various chemical mediators such as IL-6 (Guerne et al., 1989), 
prostaglandin E2 (PGE2) (Moos et al., 1999) and nitric oxide (NO) (Stefanovic-Racic et al., 
1994) from synoviocytes. IL-1b  also stimulates the production of PGE2 (Campbell et al., 1990), 
NO (Stadler et al., 1991) and metalloproteases (Tetlow et al., 2001) from chondrocytes. 
Matrix metalloproteases (MMPs) are important molecules that induce cartilage depletion in OA. 
MMP-1 and MMP-13 cleave predominantly type II collagen (Billinghurst et al., 1997), and 
MMP-3, also known as stromelysin-1, degrades proteoglycans (Okada et al., 1992). Activated 
chondrocytes in OA produce these MMPs and degrade extracellular matrix surrounding them. 
PGE2, an inflammatory mediator, is involved in the homeostasis of chondrocytes (Fulkerson et 
al., 1983) and enhances pain (Ferreira et al., 1978). Chondrocyte-derived NO directly breaks 
down cartilage matrix and induces chondrocyte apoptosis (Hashimoto et al., 1998; Pelletier et 
al., 2000). 
Nutraceutical glucosamine has been used as a supplement for the treatment of osteoarthritis for 
decades, possibly because the extracellular matrix was believed to wear out in OA cartilage. 
Many clinical results were reported (McAlindon et al., 2000) and some in vitro studies have 
been published on the effects of glucosamine on chondrocytes or articular cartilage (Piperno et 
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al., 2000; Bassleer et al., 1998; Gouze et al., 2001; Shikhman et al., 2001). Here, we evaluated 
the effects of glucosamine hydrochloride on cultured cells derived from normal cartilage, OA 
cartilage and OA synovium in terms of production of PGE2, NO, MMP-1, MMP-3, and MMP-
13. 
 
3.2 Materials and methods 
3.2.1 Chondrocyte and synoviocyte culture 
Chondrocytes and synovial cells were prepared from surgical specimens obtained during 
arthroplasty for OA and femoral neck fracture. As articular cartilage from the latter samples was 
macroscopically and microscopically normal, they were used as the normal controls. OA 
patients (n=79 had an average age of 70.1 (range 50-77 yrs) and were diagnosed as having 
primary OA. Articular changes were advanced and the patients were being treated with 
analgesics. Fracture patients (n=6) had an average age of 76.6 yrs (range 70-83). Cartilage was 
carefully cut from the subchondral bone. 
Fragments of cartilage and synovial tissue were minced to fine pieces followed by digestion in 
Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, NY) with 1 mg/ml of bacterial 
collagenase (Sigma, MO). The cells were filtered, washed, and seeded into 75 cm2 flasks 
(Becton Dickinson Labware, Bedford, UK). The cells were cultured in DMEM containing l0% 
fetal calf serum (FCS; Gibco BRL, NY), 100 units/ml penicillin (Gibco BRL), and 100 mg/ml 
streptomycin (GibcoBRL) and cells from the primary cultures were used for the experiments. 
After the cells became confluent in 24-well plates, medium was changed to 2.5% FCS/DMEM 
and the cells were stimulated with 5 ng/ml of IL-1b (Rosch, Mannheim, Germany) in the 
presence of 1, 10 or 100 mg/ml of glucosamine hydrochloride (Yaizu Marine Products, Japan) 
for 24 hours. For synoviocytes, 5, 50 and 500 mg/ml of glucosamine hydrochloride were used as 
they were considered to be less responsive to glucosamine. Supernatants were then collected to 
measure the levels of PGE2, NO, MMP-1, -3, and -13. The cells were harvested to detect COX-2 
by semi-quantitative RT-PCR and Western blot 
 
3.2.2 Measurement of PGE2, NO, MMP-1, MMP-3 and MMP-13 
PGE2 and NO were assessed by a PGE2 EIA kit (Cayman Chemical Co., MI) and a Nitrite 
colorimetric assay kit (COXIS International, Inc., OR), respectively. MMP-1, MMP-3, and 
MMP-13 were determined by ELISA or EIA kits (MMP-1 and MMP-13; Amersham Pharmacia 
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Bioteck, UK, MMP-3, Daiichi Kagaku Yakuhin, Japan). Precursor and active MMP as well as 
active complex with tissue inhibitor of metalloprotease-1 (TIMP-1) are measured with these 
systems.    . 
 
3.2.3 Preparation of mRNA and semi-quantitative PCR 
COX-2 mRNA was quantified using a Gene Specific Relative RT-PCR kit (Ambion,Inc, UK) 
following the manufacture's instruction. Briefly, mRNA was extracted from 106 chondrocytes 
using Isogen (Nippon Gene, Japan). cDNA was synthesized in a 20 ml reaction mixture 
containing 5 mg of total RNA, 2.5 mM of each dNTP, 1 mM of random hexamer primers, 40 
units of ribonuclease inhibitor (RNasin; Toyobo, Japan), and 200 units of Superscript II RT 
(Gibco BRL) at 42°C for 2 hours. The resulting cDNAs were amplified in 50 ml reaction 
mixture containing COX-2 and 18S primer pairs (included in the kit), 2.5 mM of each dNTP and 
0.3 ml of Taq polymerase (Takara, Japan) at 94°C for 30 seconds, 59°C for 30 seconds, and 
72°C for 30 seconds for 24 cycles in a PCR thermal cycler (Perkin-Elmer, CT). PCR products 
were electrophoresed on 2% agarose gels, stained with ethidium bromide (10 mg/ml), and the 
intensity of the bands were quantified by a fluoro- image analyzer, FLA-2000 (Fuji Film, Japan). 
The result was expressed as the intensity of COX-2 PCR products against those of 18S. 
 
3.2.4 Western blot for COX-2 
Normal chondrocytes in 24-well dish were stimulated by 5 ng/ml of IL-1b, in the presence of 
100 mg/ml glucosamine hydrochloride or 1 mM diclofenac. After 24 hours, cells were dissolved 
in lysis buffer (20 mM Tris, 250 mM NaCl, 1% NP-40, 1 mM DTT, 10 mM NaF, 2 mM 
Na3VO4, 10 mM sodium pyrophosphate) and sonicated for 3 seconds on ice following 
centrifugation at 3,000 rpm for 5 minutes. Supernatant was dissolved in the same amount of 
sample buffer (0.1 M Tris, 4%SDS, 12 mM DTT, 20% glycerol, 1% BPB) and boiled for 5 
minutes. Electrophoretically analyzed proteins (15 mg/lane) on 12.5% SDS-PAGE gels were 
transferred onto Nitrocellulose Membrane (BioRAD, CA). The membrane was blocked in 5% 
skim milk for 1 hour at room temperature and subsequently immunoblotted with anti-COX-2 
antibody (Cayman Chemical Co.) at a 1,000 dilution and then incubated with anti- rabbit-IgG 
antibody conjugated with HRP (Nichirei, Japan) at a 10,000 dilution for 1 hour. The membrane 
was washed 3 times between each step. Then the membrane was developed using an ECL 
system (Amersham, IL). 
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3.2.5 Statistical analysis 
Each value was from individual samples. Values were expressed as the mean ± SE. Statistical 
analysis included the Wilcoxon signed rank test for comparisons of paired values, and the Man-
Whitney U test for inter-group comparisons. 
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3.3 Results 
3.3.1 IL-1b stimulated production of PGE2, NO, MMP-1, MMP-3, and MMP-13 
With IL-1b stimulation, the level of all mediators from chondrocytes and synoviocytes increased 
dramatically, except for NO from synoviocytes. These levels and the response to IL-1b were 
higher in OA chondrocytes than in normal chondrocytes and synoviocytes. It is worth noting 
that the net level of MMP-3 in stimulated OA chondrocytes was extremely high compared to 
those of MMP-1 and MMP-13 (Fig. 1). 
 
Fig.1. PGE2, NO, MMP-1, MMP-3, and MMP-13 values in the supernatant of normal 
chondrocytes (n=6), OA chondrocytes (n=7) and OA synoviocytes (n-5) at 
baseline and after stimulation with IL-1b. Except for NO in normal chondrocytes 
and synoviocytes, IL-1b dramatically  stimulated the production of these 
mediators. Blank bars indicate the baseline and dotted bars indicate the 
stimulation. 
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3.3.2 Effects of glucosamine on PGE2 production 
Prior to assay of the effects of glucosamine hydrochloride on the production of various 
mediators, its effect on cell viability was evaluated by MTT assay (Denizot et al., 1986). Cell 
viability was not affected at concentrations ranging from 1 to 500 mg/ml (data not shown). 
PGE2 production was enhanced by IL-1 stimulation in normal chondrocytes and OA 
synoviocytes as well as OA chondrocytes. The PGE2 level in IL-1 stimulated OA chondrocyte 
cultures was 10 times higher than that in unstimulated ones. PGE2 production was suppressed by 
100 mg/ml glucosamine in normal and OA chondrocytes, whereas dexamethasone and 
diclofenac, which were tested as positive controls, almost completely inhibited stimulated PGE2  
production. IL-1b enhanced the expression of COX-2 mRNA, but glucosamine had no effect on 
this response. Dexamethasone suppressed the expression of COX-2 mRNA, whereas diclofenac 
enhanced its expression in OA chondrocytes, which may reflect a feedback regulation caused by 
diclofenac-mediated COX-2 inhibition (Fig.2). This result was also supported by Western blot 
analysis which showed that COX-2 expression was enhanced by IL-1b, and that addition of 100 
mg/ml glucosamine had no effect whereas the addition of diclofenac slightly increased the 
expression (Fig.3). 
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Fig.2. Production of PGE2 and expression of COX-2 mRNA in normal 
chondrocytes (n=6), OA chondrocytes (n=7) and OA synoviocytes (n=5). Cells 
were stimulated with IL-1b (5 ng/ml) and treated with glucosamine hydrochloride 
(1-100 mg/ml), dexamethasone (0.1 mM) or diclofenac (1 mM). Glucosamine (100 
mg/ml) suppressed the production of PGE2 in normal and OA chondrocytes. In 
synoviocytes, 500 mg/ml of glucosamine showed suppressed PGE2 production 
but this change was not significant. The expression of COX-2 mRNA was not 
affected by glucosamine, whereas dexamethasone suppressed it and diclofenac 
enhanced its expression in normal chondrocytes. Statistical analysis was 
performed using the Wilcoxon signed rank test. *p<0.05. N: normal chondrocytes, 
OA: OA chondrocytes, S: OA synoviocytes, Gluco: Glucosamine, Dex: 
Dexamethasone, Diclo: Diclofenac 
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Fig.3. The effect of glucosamine hydrochloride and diclofenac on IL-1b 
stimulated COX-2 protein expression was analyzed by Western immunoblot. 
COX-2 expression was enhanced by IL-1b stimulation; 100 mg/ml of glucosamine 
had no effect on the expression and 1 mM diclofenac slightly enhanced the 
expression. Repeated experiments showed the same results.  
 
3.3.3 Effects of glucosamine on NO production 
Glucosamine slightly suppressed of NO from IL-1 treated normal chondrocytes, whereas it did 
not affect OA chondrocytes and OA synoviocytes (Fig.4) 
Fig.4. Production of NO in normal chondrocytes (n=6), OA chondrocytes (n=7) 
and OA synoviocytes (n=5). Cells were stimulated with IL-1b (5 ng/ml) and treated 
with glucosamine hydrochloride (1-100 mg/ml) or dexamethasone (0.1 mM). 
Glucosamine (100 mg/ml) suppressed the production of NO only in normal 
chondrocytes. Statistical analysis was performed using the Wilcoxon signed-
rank test. *p<0.05. N: normal chondrocytes, OA: OA chondrocytes, S: OA 
synoviocytes, Gluco: Glucosamine, Dex: Dexamethasone 
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3.3.4 Effects of glucosamine on MMP production 
The production of MMP-1, MMP-3, and MMP-13 was measured in the supernatants of 
chondrocytes and synoviocytes. The net level of MMP-3 was the hgighest among the MMPs 
tested and the level of MMP-13 was the lowest. All MMP levels were enhanced by IL-1b. After 
stimulation with IL-1b, the production of MMP-1, -3, and -13 was partly suppressed by 100 
mg/ml glucosamine in normal chondrocytes. In OA synoviocytes, 500 mg/ml glucosamine 
suppressed the production of MMP-1, -3, and -13. Constant suppression by dexamethasone was 
shown in all cell types. MMP production was not suppressed by glucosamine at the 
concentrations to 100 mg/ml in OA chondrocytes (Fig.5). 
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Fig.5. MMP-1, -3, and -13 levels in the normal chondrocytes (n=6), OA 
chondrocytes (n=7) and OA synoviocytes (n=5). After stimulation with IL-1b (5 
ng/ml), cells were treated with various concentration (1-100 mg/ml) of 
glucosamine hydrochloride or dexamethasone (0.1 mM). Glucosamine (100 
mg/ml) showed a suppressive effect on MMP production from normal 
chondrocytes and OA synoviocytes. The Wilcoxon signed-rank test was used for 
the statistical analysis. *p<0.05. N: normal chondrocytes, OA: OA chondrocytes, 
S: OA synoviocytes, Gluco: Glucosamine, Dex: Dexamethasone 
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3.4 Discussion  
Degradation of articular cartilage is deriven by an imbalance of catabolic an anabolic factors in 
OA (Goldring, 2000). The former include proinflammatory cytokines such as IL-1 and TNF, 
proteases such as MMPs and cathepsins, and NO that induces chondrocyte apoptosis as well as 
matrix damage. IL-1 also enhanced the produciton of PGE2. In this experiment, the level of 
MMP-3 in the supernatant of stimulated OA chondrocytes was 4 mg/ml whereas its 
concentration in OA synovial fluid has been reported to be a little higher (from 13 mg/ml to 15 
mg/ ml) (Ribbens et al., 2000; Yoshihara et al., 2000). On the contrary, MMP-1 and MMP-13 
levels in the supernatant of OA chondrocytes (551.6 ng/ml and 12.8 ng/ml, respectively) were 
higher than those in OA synovial fluid (356.1 ng/ml and 5.27 ng/ml, respectively) (Yoshihara et 
al., 2000; Ito et al., 2002). Overall, OA chondrocytes showed a higher sensitivity to the 
stimulation of MMP, PGE2 and NO by IL-1 than normal chondrocytes did. This could be 
attributed to the fact that OA chondrocytes had a higher (about 2-fold) density of IL-1 receptor 
compared with normal chondrocytes (Maetel-Pellitier et al., 1992). As the cartilage samples of 
OA were derived from an advanced stage of the disease in which arthroplasty is needed, the 
chondrocytes are supposed to have been exposed to the specific condition in the OA joint for a 
long time, which may have altered their characteristics. 
PGE2 modulates cartilage degradation in the presence of IL-1 (Hardy et al., 2002) and seems to 
have a bivalent effect on chondrocytes (Abramson, 1999). PGE2 also induces inflammation and 
augments pain (Ferreira et al., 1978). The latter function is important with regard to the clinical 
effects of glucosamine on OA, as one of the major short-term effects of glucosamine is pain 
relief (Nakamura et al., 2002). PGE2 is spontaneously released from OA chondrocytes and its 
production is enhanced by IL-1 (Maetel-Pellitier et al., 1992). In this study, the production of 
PGE2 from IL-1-stimulated chondrocytes, especially chondrocytes derived from OA patients, 
was higher than that from synoviocytes. Thus, it is speculated that the source of PGE2 in the OA 
joint was chondrocytes as well as synoviocytes. The suppressive effect of glucosamine on PGE2  
production might reflect its beneficial role in the treatment of OA. 
PGE2 Synthesis is regulated by the coordination of phospholipase A2 (PLA2), COX and PGE 
synthase (PGE2 ) activities (Leslie et al., 1997; Jakobsson et al., 1999). Nonsteroidal anti-
innammatory drugs inhibit COX activity, whereas glucocorticoids suppress its expression at the 
transcriptional level. Shikhman et al. (2001) reported that 10 mM N-acetyl glucosamine 
suppressed COX-1 and COX-2, but did not observe suppressive effects on the expression of 
MAP kinases or translocation of NFkB. On the other hand, Largo et al. (2003) demonstrated 
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that glucosamine sulfate inhibited IL-1 induced NFkB activity in a dose-dependent manner and 
suppressed COX-2 expression at the concentration of 1 mg/ml. In these reports, authors used 
different glucosamine derivatives with a higher concentration than those used in this study. 
Glucosamine hydrochloride did not affect the expression of COX-2 mRNA and protein at 100 
mg/ml, thus the suppressive effect of glucosamine hydrochloride on PGE2 in this study should be 
investigated further. Phospholipase activity might be involved in this process as Piperno et al. 
clearly showed that glucosamine suppressed PLA2 activity (Piperno et al., 2000). 
Recently, Dodge et al. reported that 25 mM glucosamine sulfate suppressed MMP-3 from IL-1 
stimulated OA chondrocytes (Dodge et al., 2003) and Byron et al. demonstrated that 
glucosamine suppressed MMP-1, -3 and -13 from LPS stimulated horse chondrocytes (Byron et 
al., 2003). In this study, glucosamine was shown to suppress MMP-1, -3 and -13 in normal 
chondrocytes and OA synoviocytes. However, OA chondrocytes showed no response to 
glucosamine at 100 mg/ml. As OA chondrocytes intensely express IL-1 receptor and are 
sensitive to IL-1 stimulation (Martel-Pellitier et al., 1992), they are supposed to be less 
responsive to counteracting glucosamine. 
Nitric oxide is also a catabolic factor for extracellular matrix in articular cartilage and 
glucosamine hydrochloride slightly suppressed IL-1 induced NO, while N-acetyl glucosamine 
dramatically suppressed it (Shikhman et al., 2001). In other positive reports, the concentrations 
of glucosamine derivatives were considerably higher than those used in this study; thus it is 
possible that a higher concentration of glucosamine hydrochloride might suppress the mediators 
that we investigated. However it should be noted that high-dose glucosamine (0.25-25 mg/ml) 
impairs the metabolic activity of chondrocytes in terms of proteoglycan synthesis, cell viability 
and cell death (de Mattei et al., 2002). Though there have been no reports describing the optimal 
clinical dosage of glucosamine for the treatment of OA, excess administration could be harmful 
and concentrations of up of 100 mg/ml are supposed to be rational to investigate clinical effects 
of glucosamine. Moreover, as our data originated from human samples, the results are 
considered to reflect the practical clinical response of glucosamine. 
Our data show that glucosamine hydrochloride had pharmacological effects on chondrocytes 
and synoviocytes by inhibition of IL-1 stimulated production of PGE2, NO, MMP-1, MMP-3 
and MMP-13. Glucosamine hydrochloride (100 mg/ml) suppressed the MMP production of 
normal chondrocytes and synoviocytes but not of OA chondrocytes. It was revealed that 
glucosamine modulates the metabolism of chondrocytes and synoviocytes, and that its mode of 
Chapter III: Effects of glucosamine on PGE2, NO, and MMP production 
43 
action differs between cells and experimental conditions. These results may reflect the 
mechanism of action of glucosamine on pain relief and the prevention of articular destruction. 
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3.5 Summary 
The aim of this study was to determine the response of glucosamine hydrochloride on 
chondrocytes and synoviocytes in terms of PGE2, NO, and MMPs. Chondrocytes and 
synoviocytes were prepared form joint specimens of patients who underwent total knee 
arthroplasty for osteoarthritis (OA). Chondrocytes from patients with femoral neck fracture were 
served as a normal control. Culture cells were stimulated by 5 ng/ml of IL-1b and treated with 
various concentration of glucosamine hydrochloride (from 1 mg/ml to 500 mg/ml). PGE2, NO, 
MMP-1, MMP-3, and MMP-13 levels were evaluated in the culture supernatant. Further, the 
expression of COX-2 mRNA was studied by semi-quantitative PCR. With IL-1b stimulation, 
the levels of these mediators increased dramatically, except for NO from synoviocytes. After 
stimulation, levels of these mediators in OA chondrocytes were higher than synoviocytes and 
normal chondrocytes, and the level of MMP-3 was higher than those of MMP-1 and MMP-13. 
Glucosamine hydrochloride at a concentration of 100 mg/ml suppressed PGE2 production, and 
partly suppressed NO production. It also suppressed the production of MMPs from normal 
chondrocytes and synoviocytes but not from OA chondrocytes. In conclusion, glucosamine 
modulates the metabolism of chondrocytes and synoviocytes and its mode of action differs 
between cells and conditions.  
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4. Characterization of cells from pannus-like tissue over articular 
cartilage of advanced osteoarthritis 
 
4.1 Introduction 
Osteoarthritis (OA) is the most common form of arthropathy, and the major cause of disability 
in the elder. Histological studies of osteoarthritic joints show that the prominent change is the 
loss of hyaline cartilage from part or whole of the articular surface, accompanied by new bone 
formation (osteophyte). In addition, foci and plaques of new non-osseous  tissue were often seen 
at the surface of diseased joints, which was considered as a phenomenon of remodeling process 
(Meachim et al., 1970). The histological appearance of the new tissue is described as a pannus-
like fibrous tissue, chodroid, fibrocartilage or a form of hyaline cartilage (Meachim et al., 1970; 
Meachim, 1972; Nakata et al., 1986). Pannus is now known as invasive granulation tissue  
observed on articular surface of rheumatoid arthritis (RA) joints; however, the word ‘pannus’ 
originated in appearance like cloth that covered articular surface. Contrary to RA pannus, which 
had been extensively studied (Bresnihan et al., 1999), little attention has been paid to the non-
cartilaginous tissue covering OA cartilage. Recently, Shibakawa et al. (2003) reported that 80% 
of articular samples from OA patients had pannus- like tissue that had catabolic properties.  
Matrix metalloproteinases (MMPs) play an important role in degeneration of articular cartilage 
in OA (Woessner et al., 1991; Shlopov et al., 1997). Recent studies have shown that MMP-1, 
MMP-3 and MMP-13 were present in synovial fluid (SF) from OA patients (Toshihara et al., 
2000; Ishiguro et al., 1999; Iwase et al., 1998), and the severity of cartilage damage 
corresponded with synovial MMP activity (Maiotti et al., 2000). By detecting degraded products 
of type II collagen and proteoglycan, the presence of specific MMP activity was elucidated in 
vivo (Dahlberg et al., 2000; Freemont et al., 1999; Billinghurst et al., 1997). In OA, the  
production of these MMPs was upregulated in synovial tissue (Young et al., 2001; Wemicke et 
al., 1996), in SF cells (Tsuchiya et al., 1996), in chondrocytes (Freemont et al., 1997; Shlopov 
et al., 2000; Tetlow et al., 2001) and in pannus-like tissue on OA cartilage (Shibakawa et al., 
2003). 
In this study, we isolated cells from the pannus- like tissue on advanced OA cartilage (OA 
pannus cells) and cultivated them to investigate their phenotype and function. The production 
and expression of collagen, aggrecan and MMPs (MMP-1, MMP-3, and MMP-13) by these cells 
were evaluated and compared to that of chondrocytes from the same cartilage samples. 
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4.2 Patients and methods 
4.2.1 Cartilage  
Articular cartilage specimens were obtained from 21 patients who met the criteria of American 
College of Rheumatology for OA (Altman et al., 1986) and underwent arthroplasty. All the 
samples were from medial type knee OA or hip OA in advanced stage. Macroscopically, 15 of 
the 21 (71.4%) specimens had pannus- like tissue varying in size and locations, and we used 5 of 
the 15 specimens, which had enough tissue to be isolated (four knee joints and one hip joint, 
four females and one male, mean age of 76 years ranging from 56 to 94 years). All the samples 
were obtained with informed consent from the patients, and the  study protocol was approved by 
the institutional ethical committee. 
 
4.2.2 Cell preparation  
Pannus- like tissue was grazed off bluntly and gently from the residual hyaline cartilage as a 
thick material (Fig. 1). As pannus- like tissue occupied less than 30% of the surface of residual 
cartilage in OA with little quantity, it was difficult to detach enough samples discriminating two 
tissue types, fibrous type and vascular type, both of which were previously found (Shibakaawa 
et al., 2003). Attention was paid not to scrape residual cartilage to cause contamination. OA 
pannus cells were prepared as follows. Pannus- like tissue was minced and then digested by 
rotating overnight at 37°C in Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, NY) 
containing 1 mg/ml of bacterial collagenase (Sigma, MO). A part of the removed tissue was 
analyzed histologically to confirm that no piece of hyaline cartilage was included. The cells 
released by enzymatic digestion were filtered through a sterile nylon strainer (Becton Dickinson, 
NJ), washed, and centrifuged. The pellet was seeded into a 90 mm diameter dish (Sumitomo 
Medical Co., Tokyo) at a density of 2-4×105-4×105 cells/dish and cultivated at 37°C in a 
humidified atmosphere of 5% CO2. The culture medium used was DMEM containing 10% heat-
inactivated fetal calf serum (FCS; Gibco BRL) and 1% penicillin/streptomycin (Gibco BRL). 
Medium was replaced every week, and cells were used within the second passages. 
Chondrocytes were isolated from the residual hyaline cartilage taken from the articular region 
that was not covered with soft tissue. Fibroblast- like synoviocytes from synovium of the same 
samples were used as controls. 
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Fig. 1. Collection of pannus-like tissue from articular surface of lateral tibial 
condyle of the knee sample. The tissue was removed bluntly and gently from 
residual cartilage using a scalpel. 
 
4.2.3 Safranin-O staining and immunostaining  
Cells were seeded in eight-well chamber slides (Nunc, Naperville, IL) at a concentration of 
2×104 cells per well and were cultured for 3-5 days. The slides were fixed using 4% 
formaldehyde in phosphate buffered saline (PBS) containing 0.1% saponin at room temperature 
for 30 min. Safranin-O staining was performed according to the method described previously 
(Xue et al., 1997). Immunostaining was performed using HistoMark kits (streptavidin-
horseradish peroxidase; KPL, Gaithersburg, MD). After fixation, slides were preincubated with 
heat-inactivated 10% goat serum at room temperature for 30 min, and then incubated at room 
temperature for 1 h with mouse anti-human collagen type I, collagen type II (Chemocon Int. Inc., 
Temecula, CA, 20 µg/ml), vimentin (Sigma, MO, 1:200) or anti-human MMP-3 (Fuji-Chemical 
Co., Japan, 10 µg/ml) monoclonal antibodies. Slides were washed twice with 0.04 M Tris 
buffered saline (pH 7.6) containing 0.1% saponin, then sequentially incubated twice with a 
biotinylated goat anti-mouse immunoglobulin and streptavidin-peroxidase conjugate at room 
temperature for 30 min. The streptavidin-peroxidase was then visualized using 
diaminobenzidine. Slides were counterstained with hematoxylin and evaluated with a bright-
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field microscope. For histochemical or immunohistochemical study, 5 µm thick sections of 
paraffin-embedded specimens were prepared and subjected to staining as mentioned above. 
 
4.2.4 Detection of MMP-1, MMP-3, and MMP-13 of enzyme-linked 
immunosorbent assay (ELISA) 
The levels of MMP-1, MMP-3 and MMP-13 in supernatants were evaluated with commercially 
available ELISA kits according to the instructions of the manufacturer (Amersham Pharmacia 
Biotech, UK). These assays were capable of measuring each free proMMP as well as active 
MMP-TIMP-1 complex. 
 
4.2.5 Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis 
Total RNA was extracted from 1×106 isolated cells using the single-step guanidinium 
thiocyanate-phenol-chloroform method (RNAzol B solution; Tel-Test, TX). RNA was 
precipitated in ethanol, recovered by centrifugation, resuspended in 10 µl of sterile water, and 
evaluated spectrophotometrically for quantity and purity. First-strand complementary DNA 
(cDNA) was synthesized in a 20-µl reaction mixture containing 5 µg of total RNA, 2.5 mM of 
each dNTP, 1 mM of random hexamer primers, 40 units of ribonuclease inhibitor (RNasin; 
Toyobo, Tokyo, Japan), and 200 units of Superscript II RT (Gibco BRL), by incubation at 42°C 
for 2 h. The resulting cDNA (2 µl) was subjected to PCR using Taq DNA polymerase (TaKaRa, 
Japan) and the specific primers for Col I, Col II, aggrecan, and MMPs. PCR for Col I, Col II and 
aggrecan was performed for 35 cycles at 94°C for 30 s, 56°C for 30 s, and 72°C for 30 s, and  
MMPs were amplified in a protocol of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min for 
22 cycles to yield amplification in the linear range, in a PCR thermal cycler (TaKaRa) (Hellio et 
al., 2001). In each experiment, amplification of cDNA for the housekeeping gene GAPDH was 
used as an internal standard. The primer sequences are listed in Table I (Chano et al., 1998; 
Konttinen et al., 1999; Fujisawa et al., 1999). PCR products were electrophoresed on 1.5% 
agarose gels, stained with ethidium bromide (10 mg/ml), and bands were visualized and 
photographed under ultraviolet illumination. The intensity of signal was quantified by an image  
analyzer, FLA 2000 (Fuji Film, Japan). 
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Table I 
Primer sequences used for reverse transcription-polymerase chain reaction 
 
Primer sequences (5'-3') Fragment    Fragment 
size (bp) 
Type II procollagen 
  Sense: 5'-AACTGGCAAGCAAGGAGACA-3'       621 
  Antisense: 5'-AGTTTCAGGTCTCTGCAGGT-3' 
Aggrecan 
  Sense: 5'-ATGCCCAAGACTACCAGTGG-3'      501/318 
  Antisense: 5'-TCCTGGAAGCTCTTCTCAGT-3' 
Type I procollagen 
  Sense: 5'-TGACGAGACCAAGAACTG-3'        599 
  Antisense: 5'-CCATCCAAACCACTGAAACC-3' 
MMP-1 
  Sense: 5'-CTGAAGGTGATGAAGCAGCC-3'        428 
  Antisense: 5'-AGTCCAAGAGAATGGCCGAG-3' 
MMP-3 
  Sense: 5'-CCTCTGATGGCCCAGAATTGA-3'       440 
  Antisense: 5'-GAAATTGGCCACTCCCTGGGT-3' 
MMP-13 
  Sense: 5'-CTATGGTCCAGGAGATGAAG-3'        390 
  Antisense: 5'-AGAGTCTTGCCTGTATCCTC-3' 
GAPDH 
  Sense: 5'-CCACCCATGGCAAATTCCATGGCA-3'       598 
  Antisense: 5'-TCTAGACGGCAGGTCAGGTCCACC-3' 
 
4.2.6 Statistical analysis  
For statistical analysis, Wilcoxon signed-ranks test was used to compare paired values and 
Mann-Whitney test for non-paired samples. 
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4.3 Results 
4.3.1 Macroscopic and microscopic findings of articular surface in OA and 
RA 
Macroscopically, the pannus- like tissue spread as a foci or plaque over residual hyaline cartilage 
in some OA samples [Fig. 2(C)]. Though there were samples lacking soft tissue covering [Fig. 
2(A and B)], pannus- like tissue was found at the margins of articular surface or in more central 
areas [Fig. 2(C)], unlike RA pannus that spreads diffusely and invasively all over the articular 
surface with local bleeding [Fig. 2(E)]. Whereas RA pannus showed hypervascularity with 
infiltrating inflammatory cells accompanied by lymph follicles [Fig. 2(F)], pannus-like tissue of 
OA had less vascularity and fibrous property [Fig. 2(D)]. As is shown in the previous report [5], 
pannus- like tissue in OA was divided into two tissue types, fibrous type and vascular type, and 
was negative for proteoglycan presented by safranin-O staining. Contrary to cells infiltrating RA 
pannus, cells in OA pannus tissue were negative for CD68 (data not shown). The thickness of 
pannus over OA cartilage varied from only a thin layer to up to 5 mm. 
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Fig. 2. Macroscopic (A, C and E) and microscopic (B, D and F; hematoxylin and 
eosin staining) views of articular surface of morbid joints. (A) and (B) show 
osteoarthritic knee joint without soft tissue from a 56-year-old male patient. 
Defect of cartilage is demarcated by distinct border of residual cartilage and 
lacerated surface is exposed directly. (C) and (D) show osteoarthritic knee joint 
with pannus-like tissue (arrowhead) from a 68-year-old female patient. Articular 
cartilage was partly covered with soft tissue like a cloth or a carpet. Histological 
finding is fibrous (fibrous type according to previous study[5]). (E) and (F) show 
rheumatoid arthritic knee joint from a 44-year-old patient with RA pannus. 
Articular surface was covered with invasive soft tissue with local bleeding. 
Histological findings show hypervascularity and infiltration of inflammatory cells. 
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4.3.2 Expression of type I collagen, type II collagen, vimentin, and 
proteoglycan in OA pannus cells   
The previous study showed that pannus- like tissue of OA expressed type I collagen but not type 
II collagen or proteoglycan (Shibakawa et al., 2003). In the present study, the expression of 
chondrocyte specific molecules, type II collagen and aggrecan, as well as type I collagen and 
vimentin was investigated in OA pannus cells by RT-PCR and immunocytochemistry.  
RT-PCR showed that not only type II collagen and aggrecan, but also type I collagen was 
expressed in OA pannus cells in five samples obtained, though the intensity of type II collagen 
was relatively weak; on the other hand, chondrocytes expressed type II collagen and aggrecan,  
and synovial samples expressed only type I collagen in all samples tested. Figure 3 shows a 
representative result from five different samples. 
 
Fig. 3. RT-PCR image of type I collagen (Col I), type II collagen (Col II) and 
aggrecan expression in articular components of OA. Fibroblast-like synoviocytes 
(A), OA pannus cells (B) and chondrocytes (C). These cells were derived from the 
same patient. 
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In immunocytochemistry, OA pannus cells were faintly stained by safranin-O in two of the five 
samples; on the other hand, chondrocytes were strongly stained in all the samples. Moreover, 
OA pannus cells were positive for type I collagen, type II collagen and also vimentin (Fig. 4). 
Synoviocytes were only positive for type I collagen and 
chondrocytes were positive for safranin-O and type II collagen. Vimentin is a marker for cells of 
mesenchymal origin and positive for mesenchymal adherent cells in RA SF (Marinoya-
Mutafchieya et al., 2000), whereas its expression was quite low in OA synoviocytes (Ritchlin et 
al., 1994). In this study, only OA pannus cells were positive for vimentin suggesting that they 
are of mesenchymal origin. 
 
Fig. 4. Representative picture of safranin-O staining and immunostaining for type 
II collagen (Col II), type I collagen (Col I) and vimentin in articular components of 
OA. Fibroblast-like synoviocytes, OA pannus cells, and chondrocytes. Bar=50 
µm. 
 
Synoviocyte
s 
OA pannus 
cells 
Chondrocytes 
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4.3.3 Expression and production of MMP-1, MMP-3 and MMP-13 by OA 
pannus cells 
MMP-3 and IL-1b  were positive in pannus- like tissue of OA, this tissue was speculated to have 
catabolic rather than anabolic property (Shibakawa et al., 2003). Thus we further investigated 
the expression and production of MMPs (MMP-1, -3 and -13) by isolated cells from the tissue. 
RT-PCR analysis revealed that MMP-1, MMP-3 and MMP-13 were expressed in all OA pannus 
cell samples with various intensities [Fig. 5(A)]. In contrast, four of the five samples and only 
one sample expressed MMP-1 and MMP-3, respectively, in OA chondrocytes. All OA pannus  
cell samples expressed MMP-13. Although no significant difference was found in relative 
intensity, there was a tendency for MMP-3 to be higher and MMP-13 to be lower in OA pannus 
cells [Fig. 5(B)]. 
 
 
Fig. 5. (A) RT-PCR analysis for MMP-1, MMP-3 and MMP-13 expression in OA 
pannus cells (lanes 1-5) and chondrocytes (lanes 6-10) from OA patients. M, 
molecular weight marker; N, negative control (no template); P, positive control 
(TNFa-stimulated chondrocytes). (B) Intensity of the signals analyzed by an 
image analyzer. Values were intensity relative to that of GAPDH. Though no 
significant difference was found, there was a tendency for MMP-3 to be higher 
and MMP-13 to be lower in OA pannus cells. 
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The expression of MMP-1, MMP-3 and MMP-13 in OA pannus cells was also confirmed by 
immunocytochemical study. OA pannus cells were revealed to express these MMPs and the 
expression of MMP-3 and -13 was stronger [Fig. 6(A–D)]. As MMP-3 was revealed to be the 
major MMP produced from isolated chondrocytes stimulated with IL-1 or TNF (Mitchell et al., 
1993), in vivo localization was confirmed in three samples by immunohistochemistry. A 
representative picture showed that a considerable number of cells in pannus- like tissue were 
positive for MMP-3, while fewer chondrocytes were positive in hyaline cartilage underlying the 
tissue [Fig. 6(E)]. 
 
Fig. 6. Immunostaining of MMPs in OA pannus cells (A-D) and MMP-3 in OA 
cartilage (E). (A) MMP-1, (B) MMP-3, (C) MMP-13; (D) control. 
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The production of MMP-1, MMP-3 and MMP-13 from OA pannus cells and chondrocytes in 
culture supernatant was also analyzed by ELISA. As shown in Fig. 7, the production of MMP-3 
was significantly higher in OA pannus cells; however, no significant difference was shown in 
other MMPs. The levels of MMP-1 and MMP-13 were relatively low compared with those of 
MMP-3. 
 
Fig. 7. MMP-1, MMP-3 and MMP-13 productions in vitro by OA pannus cells (white 
bar) and chondrocytes isolated from OA patients (black bar). Values are the 
concentration of each MMP in the supernatant of cultured cells and expressed as 
the mean and SD. Statistical analysis was performed by Wilcoxon signed-ranks 
test (*P<0.05). 
 
4.4 Discussion 
Shibakawa et al. (2003) showed that pannus- like tissue was found on OA cartilage, 
preferentially located in the marginal region of the joint and could be classified into the vascular 
type and the fibrous type. From the detailed histological observation, they speculated that the 
tissue was reparative in the earlier stage of OA, but changed to be catabolic after the long-term 
exposure to factors such as cytokines or growth factors involved in OA (Shibakawa et al., 2003). 
Pannuslike tissue in OA was different from RA pannus in the following ways: (1) it often 
occurred as foci or plaque over cartilage surface, unlike RA pannus which distributed diffusely 
over the cartilage; (2) its cell density was less than that of RA pannus, especially on the border 
of original hyaline cartilage; and (3) in contrast to RA pannus, neither lymphocyte follicles nor 
CD68+ cells were found.  
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In regard to the incidence of pannus- like tissue, Meachim and Osborne examined 20 
osteoarthritic femoral heads and reported that soft tissue, varying in pattern from fibrous to 
loose-textured, was found in all the specimens and occupied 10-55% of the diseased joint 
surface1,2. In our study, articular surface was observed macroscopically and pannus- like tissue 
was found in 71.4% of joint samples. The incidence may vary according to the stage of the  
disease and the joint examined. Anyway, the exact incidence of pannus occurring in early stage 
OA needs to be further investigated in arthroscopic study or using an animal model. 
As the property of pannus- like tissue was different from that of hyaline cartilage, we further 
investigated the cells isolated from this tissue. We found that OA pannus cells strongly 
expressed a fibroblastic marker, type I collagen;  however, they also expressed type II collagen 
and aggrecan mRNA to some extent. Thus, OA pannus cells shared some properties of 
chondrocytes. OA pannus cells might include heterogeneous cells, unlike chondrocytes, 
considering the fact that pannus-like tissue of OA was classified into fibrous type and vascular 
type; however, in situ properties of both were similar (Shibakawa et al., 2003).  
As for the origin of pannus- like tissue of OA, it can spread over the joint surface from synovial 
tissue at the articular margins or it may be caused by fibrous metaplasia of cartilage as it shared 
the common property of chondrocytes. Another candidate is soft tissue of subarticular origin 
that gains access to the surface through gaps in the bone [1,2] (Meachim et al., 1970; Meachim,, 
1972). The fact that only OA pannus cells expressed vimentin, a mesenchymal marker, supports 
the possibility that its origin is subarticular mesenchymal cells. 
As mentioned above, pannus- like tissue of OA had a catabolic property, although it is 
speculated to be reparative in the earlier stage of this disease. A previous report also described 
cartilage erosion by this tissue (Fassbender, 1975). In this regard, it might have, partly, some 
common properties as RA pannus in cartilage destruction. In this study, we confirmed the  
expression of MMP-1 -3 and -13, and showed that OA pannus cells as well as OA chondrocytes 
expressed MMPs; especially, OA pannus cells produced more MMP-3 than OA chondrocytes at 
protein level. Distinctive expression of MMP-3 was found only in one sample by RT-PCR, 
which was inconsistent with the result from ELISA, as MMP-3 was detected in the culture 
supernatant of all samples as shown in Fig. 7. One of the reasons  for this inconsistency might be 
insufficient amplification (22 cycles) to get the semi-quantitative results. MMP-3 expression 
was detected in OA chondrocytes amplified for 35 cycles (data not shown). 
Since it is well known that these MMPs play a crucial role in cartilage damage by degrading 
cartilage components including collagen types II, IX, XI and proteoglycan (Otterness et al., 
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2000; Konttinen et al., 1999), our results support the previous speculation that pannus- like tissue 
of OA is involved in further cartilage degradation, especially in advanced OA. This leads to the 
hypothesis that cartilage defects may be bridged by fibrous tissue for repair, but continual joint 
movement or unfavorable circumstances such as exposure to cytokines may make it unlikely for 
a repair process to succeed. The expression of proteoglycan and type II collagen suggests the 
possibility of repair by this tissue in some condition, even though catabolic factors are also 
expressed. 
In conclusion, we demonstrated pannus- like tissue over OA cartilage, and the cells isolated from 
this tissue shared properties of mesenchymal cells and chondrocytes to some extent. In addition, 
OA pannus may be involved in cartilage degradation in OA by producing MMPs. Our results 
shed light on the role of soft tissue in cartilage degradation in OA, suggesting the possibility of 
new therapeutic strategy in OA, by targeting pannus-like tissue of OA to prevent cartilage from 
further degradation. 
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4.5 Summary 
The aims of this study were to identify the characteristics of cells isolated from pannus- like soft 
tissue on osteoarthritic cartilage (OA pannus cells), and to evaluate the role of this tissue in 
Osteoarthritis (OA). OA pannus cells were isolated from pannus- like tissues in five joints 
obtained during arthroplasty. The phenotypic features of the isolated cells were characterized by 
safranin-O staining and immunohistochemical studies. Expression of MMP-1, MMP-3 and 
MMP-13 was also assessed using reverse transcriptase-polymerase chain reactions (RT-PCR), 
enzyme-linked immunosorbent assay (ELISA) and immunocytochemistry. Foci and plaque 
formation of pannus-like tissue over cartilage surface were found in 15 of 21 (71.4%) OA joints 
macroscopically, and among them, only five samples had enough tissue to be isolated. OA 
pannus cells were positive for type I collagen and vimentin, besides they also expressed type II 
collagen and aggrecan mRNA. Spontaneous expression of MMP-1, MMP-3 and MMP-13 was 
detected in OA pannus cells. Similar or higher levels of MMPs were detected in the supernatant 
of cultured OA pannus cells compared to OA chondrocytes, and among these MMP-3 levels 
were relatively higher in OA pannus cells. Immunohistochemically, MMP-3 positive cells 
located preferentially in pannus- like tissue on the border of original hyaline cartilage. In 
conclusion, these results showed that OA pannus cells shared the property of mesenchymal cells 
and chondrocytes; however, their origin seemed different from chondrocytes or synoviocytes. 
The spontaneous expression of MMPs suggests that they are involved in the articular 
degradation in OA. 
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Concluding remarks 
Summary 
In this study, the roles of articular components in OA progression were investigated in order to 
clarify the mode of action of anti-OA drugs, specifically HA and glucosamine.chondrocytes and 
synoviocytes. In addition, novel cartilage destruction pathways were identified to seek new 
approach of anti-OA drugs. 
 
In Chapter I, it was demonstrated that HA suppresses IL-1b-induced production of MMP-1 and 
RANTES from OA chondrocytes in a molecular-weight-dependent manner. It was also revealed 
that sensitivity of the cells to HA depended on their expression level of CD44.  
 
In Chapter II, it was revealed that a direct contact of chondrocytes and T cells stimulates 
production of MMPs and RANTES and there are circumstantial evidences of possible encounter 
of these cells in vivo. This interaction is suggested to be a novel cartilage destruction pathway in 
OA.  
 
In Chapter III, it was shown that glucosamine hydrochloride modulated IL-1 stimulated 
production of PGE2, NO, MMP-1, MMP-3 and MMP-13 from chondrocytes and synoviocytes, 
and its mode of action differed between cells and conditions. The results also suggested that 
chondrocytes, as well as synoviocytes, are source of PGE2. 
 
In Chapter IV, the characteristics of cells isolated from pannus- like tissue were identified. Since 
the OA pannus cells spontaneous ly secrete MMPs, this tissue is considered to be involved in the 
articular degradation in advanced OA. 
 
In conclusion, we demonstrated pharmacological actions of HA and glucosamine on 
chondrocytes and synoviocytes. Our results also clarified that chondrocytes and synoviocytes 
react differently to anti-OA drugs, depending on cell types and cell conditions. These results can 
be used not only for rationalizing these treatments, but also for explaining the existence of 
“responder” and “non-responder” to HA and glucosamine treatments. In addition, our study 
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suggested 2 novel cartilage destruction pathways: chondrocyte-T cell interaction and OA 
pannus- like tissue. Although we need further investigation on these new pathways, our results 
provides new approach for exploring novel anti-OA drugs.  
 
Future prospects 
In the present study, we used isolated human chondrocytes and synoviocytes. It has been 
reported that the phenotype and function of chondrocytes are changed when they are cultured in 
monolayer. Although it is unlikely that cells in our experiments totally changed their characters 
as we used the cells within 2nd passage (mostly 1st passage), we might need to demonstrate 
similar results using cartilage explants, instead of isolated cells, to cast aside this concern.  
We demonstrated that OA pannus- like tissues were observed with a high frequency only in 
advanced OA. But it is important to investigate the incidence of this tissue and identify cellular 
characteristics of them to clarify its role in OA progression. There will be an ethical hurdle if 
one might attempts an arthroscopic study, therefore, MRI could be an alternative. 
 
Current OA treatment is symptomatic therapy, and there is no curative treatment so far. There is 
a strong need for a novel anti-OA drug that is effective and safe. I hope this study provides 
useful information to develop new OA drugs. 
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